Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2025
|
| Materias: | |
| Acceso en línea: | https://onlinelibrary.wiley.com/doi/10.1111/cod.70063 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1867017117380902912 |
|---|---|
| author | Han‐Bi Kim Min‐Gyu Choi Hyung‐Woo Jo Ji‐Young Um So‐Yeon Lee Bo‐Young Chung Chun‐Wook Park Hye‐One Kim |
| author_facet | Han‐Bi Kim Min‐Gyu Choi Hyung‐Woo Jo Ji‐Young Um So‐Yeon Lee Bo‐Young Chung Chun‐Wook Park Hye‐One Kim Han‐Bi Kim Min‐Gyu Choi Hyung‐Woo Jo Ji‐Young Um So‐Yeon Lee Bo‐Young Chung Chun‐Wook Park Hye‐One Kim |
| collection | Wiley Open Access |
| contents | A Retrospective Cohort Study on the Efficacy of Pregabalin in Patients With Sensitive Skin Han‐Bi Kim Min‐Gyu Choi Hyung‐Woo Jo Ji‐Young Um So‐Yeon Lee Bo‐Young Chung Chun‐Wook Park Hye‐One Kim Contact Dermatitis ABSTRACT Background Sensitive skin syndrome (SSS) is a common disorder showing abnormal responses to stimuli, without approved treatments and unclear neuropathic mechanisms. Objective To evaluate pregabalin efficacy in reducing SSS symptoms and identify predictors of treatment response. Methods A systematic retrospective cohort of 112 clinically diagnosed SSS patients (mean age 40.5 years). The primary outcome was sensitive scale‐10 (SS‐10) score change at 12 weeks; response was defined as a ≥ 30% reduction. Secondary outcomes included dermatology life quality index (DLQI), hospital anxiety and depression scale (HADS), skin biophysical parameters, von Frey thresholds and facial erythema. Results At 12 weeks, 46.4% of patients responded. Most patients (86.6%) received less than 75 mg/day. Higher baseline SS‐10 scores ( r = 0.5) and tingling symptoms ( p = 0.050) were associated with greater response, while discomfort was associated with non‐response ( p = 0.005). SS‐10 scores correlated with DLQI ( r = 0.49) and total HADS ( r = 0.29). Reduced von Frey thresholds ( r = −0.28) and increased facial erythema ( r = 0.39) were observed in responders. Conclusion Pregabalin improved symptoms in SSS, supporting its potential role in managing neuropathic features and reinforcing the neurogenic hypothesis underlying its therapeutic mechanism. 10.1111/cod.70063 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1111/cod.70063 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_cod_70063 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | A Retrospective Cohort Study on the Efficacy of Pregabalin in Patients With Sensitive Skin Han‐Bi Kim Min‐Gyu Choi Hyung‐Woo Jo Ji‐Young Um So‐Yeon Lee Bo‐Young Chung Chun‐Wook Park Hye‐One Kim Contact Dermatitis A Retrospective Cohort Study on the Efficacy of Pregabalin in Patients With Sensitive Skin Han‐Bi Kim Min‐Gyu Choi Hyung‐Woo Jo Ji‐Young Um So‐Yeon Lee Bo‐Young Chung Chun‐Wook Park Hye‐One Kim Contact Dermatitis ABSTRACT Background Sensitive skin syndrome (SSS) is a common disorder showing abnormal responses to stimuli, without approved treatments and unclear neuropathic mechanisms. Objective To evaluate pregabalin efficacy in reducing SSS symptoms and identify predictors of treatment response. Methods A systematic retrospective cohort of 112 clinically diagnosed SSS patients (mean age 40.5 years). The primary outcome was sensitive scale‐10 (SS‐10) score change at 12 weeks; response was defined as a ≥ 30% reduction. Secondary outcomes included dermatology life quality index (DLQI), hospital anxiety and depression scale (HADS), skin biophysical parameters, von Frey thresholds and facial erythema. Results At 12 weeks, 46.4% of patients responded. Most patients (86.6%) received less than 75 mg/day. Higher baseline SS‐10 scores ( r = 0.5) and tingling symptoms ( p = 0.050) were associated with greater response, while discomfort was associated with non‐response ( p = 0.005). SS‐10 scores correlated with DLQI ( r = 0.49) and total HADS ( r = 0.29). Reduced von Frey thresholds ( r = −0.28) and increased facial erythema ( r = 0.39) were observed in responders. Conclusion Pregabalin improved symptoms in SSS, supporting its potential role in managing neuropathic features and reinforcing the neurogenic hypothesis underlying its therapeutic mechanism. 10.1111/cod.70063 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | A Retrospective Cohort Study on the Efficacy of Pregabalin in Patients With Sensitive Skin |
| topic | Contact Dermatitis |
| url | https://onlinelibrary.wiley.com/doi/10.1111/cod.70063 |